Latest Impairment News

Aurizon updates its FY2025 EBITDA guidance to approximately $1.575 billion, reflecting volume and receivables adjustments, while announcing a strategic leadership restructure to unify Bulk and Containerised Freight operations.

Kip McGrath Education Centres announces exit from its unprofitable USA operations while reporting improved underlying EBITDA for FY25, alongside CEO transition costs and property lease provisions.

Collins Foods delivered resilient FY25 results with solid revenue growth and a strategic pivot towards German market expansion, while addressing profitability challenges in the Netherlands.

Collins Foods reported a record $1.52 billion revenue for FY25 with flat EBITDA despite tough market conditions, while signaling optimism for low to mid-teens NPAT growth in FY26.

Collins Foods Limited reported record revenue of $1.52 billion for FY25, up 2.1%, but statutory net profit plunged 88.5% due to significant impairments and wage provisions. The company declared a fully franked final dividend of 15 cents per share, signaling confidence despite challenges.

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

Metcash Limited reported an 8.9% rise in FY25 sales revenue to $17.3 billion and an 8.6% increase in underlying EBITDA, driven by strong Food pillar growth and the acquisition of Superior Foods. However, declines in Liquor and Hardware EBIT tempered overall profit growth.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

Clean Seas Seafood updates shareholders on a revised equity conversion ratio for the Yumbah scrip alternative following significant impairment charges by Yumbah Aquaculture. The scheme meeting is now set for 8 July 2025.

Clean Seas Seafood updates shareholders on a lower scrip alternative ratio following Yumbah Aquaculture’s significant asset impairments, while the scheme meeting is postponed to early July.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.